Literature DB >> 15736451

Elevated serum beta-defensins concentrations in patients with lung cancer.

Yasuji Arimura1, Jun-ichi Ashitani, Shigehisa Yanagi, Masatoshi Tokojima, Koh Abe, Hiroshi Mukae, Masamitsu Nakazato.   

Abstract

BACKGROUND: Beta-defensins (HBDs) are expressed in lung epithelial cells and act as antimicrobial agents. Most lung cancers that originate from pulmonary epithelial cells may produce HBDs.
MATERIALS AND METHODS: We measured serum HBD-1 and HBD-2 levels in healthy subjects (HS), patients with lung cancer and patients with pneumonia by radioimmunoassay.
RESULTS: Serum HBD-1 levels were higher in patients with lung cancer than HS and patients with pneumonia. Serum HBD-2 levels were higher in patients with lung cancer than HS. When cut-off values for positive HBD-1 were set at mean + 2SD of HS, the sensitivity and specificity of HBD-1 for the whole group of patients with lung cancer were 76.4 and 94.0%, respectively, and the proportion of patients with HBD-1-positive lung cancer and clinical stage I was 69.2%.
CONCLUSION: Serum HBDs levels were high in patients with lung cancer and the serum HBD-1 level could be used as an auxiliary diagnostic tool for lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15736451

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance?

Authors:  Maria S Zharkova; Dmitriy S Orlov; Olga Yu Golubeva; Oleg B Chakchir; Igor E Eliseev; Tatyana M Grinchuk; Olga V Shamova
Journal:  Front Cell Infect Microbiol       Date:  2019-04-30       Impact factor: 5.293

2.  Sphingosine kinase-1 is required for toll mediated beta-defensin 2 induction in human oral keratinocytes.

Authors:  Manjunatha R Benakanakere; Jiawei Zhao; Johnah C Galicia; Michael Martin; Denis F Kinane
Journal:  PLoS One       Date:  2010-07-09       Impact factor: 3.240

3.  PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer.

Authors:  Sudeep K Bose; Willietta Gibson; Rebecca S Bullard; Carlton D Donald
Journal:  Mol Immunol       Date:  2008-12-31       Impact factor: 4.407

4.  Effect of human beta-defensin-3 on head and neck cancer cell migration using micro-fabricated cell islands.

Authors:  Kevin Wang; Joanne H Wang; Harihara Baskaran; Russell Wang; Rick Jurevic
Journal:  Head Neck Oncol       Date:  2012-06-28

5.  Pattern of mRNA expression of beta-defensins in basal cell carcinoma.

Authors:  T Gambichler; M Skrygan; J Huyn; F G Bechara; M Sand; P Altmeyer; A Kreuter
Journal:  BMC Cancer       Date:  2006-06-23       Impact factor: 4.430

Review 6.  Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer.

Authors:  Amelia J Tesone; Nikolaos Svoronos; Michael J Allegrezza; Jose R Conejo-Garcia
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

Review 7.  The overlapping roles of antimicrobial peptides and complement in recruitment and activation of tumor-associated inflammatory cells.

Authors:  Izzat A M Al-Rayahi; Raghad H H Sanyi
Journal:  Front Immunol       Date:  2015-01-22       Impact factor: 7.561

8.  Elevated Concentration of Defensins in Hepatitis C Virus-Infected Patients.

Authors:  Ehab H Mattar; Hussein A Almehdar; Abdullah A AlJaddawi; Isam ElDin M Abu Zeid; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2016-06-20       Impact factor: 4.818

Review 9.  Defensins: A Double-Edged Sword in Host Immunity.

Authors:  Dan Xu; Wuyuan Lu
Journal:  Front Immunol       Date:  2020-05-07       Impact factor: 7.561

10.  Subclassification and Detection of New Markers for the Discrimination of Primary Liver Tumors by Gene Expression Analysis Using Oligonucleotide Arrays.

Authors:  Holger G Hass; Ulrich Vogel; Michael Scheurlen; Jürgen Jobst
Journal:  Gut Liver       Date:  2018-05-15       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.